{"product_id":"prof-vrio-analysis","title":"Profound Medical Corp. (PROF): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to sustained success, this VRIO analysis distills the core competitive advantage of Profound Medical Corp. (PROF) - are its resources truly Valuable, Rare, Inimitable, and Organized? Read on to uncover the definitive assessment of its market power and what it means for its future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e1. TULSA-PRO${\\circledR}$ Core Technology Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at a core asset that could genuinely shift a segment of the medical device market, and that’s why we need to break down the TULSA-PRO${\\circledR}$ platform using VRIO. Honestly, the early results suggest this isn't just another gadget; it's a platform with staying power, but we need to confirm the barriers.\u003c\/p\u003e\n\n\u003cp\u003eThe direct takeaway is that the TULSA-PRO${\\circledR}$ platform currently exhibits a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e due to its unique technological integration, which is supported by a growing commercial footprint, evidenced by \u003cstrong\u003e70\u003c\/strong\u003e installed systems as of Q3-2025.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment: TULSA-PRO${\\circledR}$ Platform\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this technology stacks up across the four dimensions:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eDimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eKey Supporting Data\/Reasoning\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eOffers incision- and radiation-free treatment for the entire prostate disease spectrum, potentially becoming a mainstream modality.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eThe combination of real-time MRI guidance with robotically-driven, transurethral ultrasound ablation is unique; it is the \u003cstrong\u003eonly\u003c\/strong\u003e AI-powered, MRI-guided robotic system for prostate treatment.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh Cost\/Difficulty\u003c\/td\u003e\n    \u003ctd\u003eProtected by patents and requires significant, specialized R\u0026amp;D investment to replicate the precision of the integrated hardware, software, and closed-loop feedback control.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eThe company is clearly organized around commercializing this platform, evidenced by \u003cstrong\u003e70\u003c\/strong\u003e systems installed as of Q3-2025 and a goal of at least \u003cstrong\u003e75\u003c\/strong\u003e by year-end.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eThe deep, proprietary integration creates a strong, durable barrier to entry against current surgical or radiation alternatives.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue and Rarity: The Tech Edge\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eValue\u003c\/strong\u003e is clear: it’s an incision-free, radiation-free procedure that uses precise sound absorption technology to heat tissue to \u003cstrong\u003e55-57°C\u003c\/strong\u003e, aiming to preserve urinary continence and sexual function. This patient-centric approach is a huge draw. For \u003cstrong\u003eRarity\u003c\/strong\u003e, you can’t just buy the pieces off the shelf. Profound Medical Corp. has created the \u003cstrong\u003eonly\u003c\/strong\u003e system that marries AI-enhanced planning, robotic control, and real-time MRI feedback for this specific purpose.\u003c\/p\u003e\n\u003cp\u003eThe clinical flexibility supports this value proposition:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTreats prostate cancer, BPH, or hybrid cases.\u003c\/li\u003e\n\u003cli\u003eCan handle prostates up to \u003cstrong\u003e250cc\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSupported by over \u003cstrong\u003e67\u003c\/strong\u003e peer-reviewed publications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability and Organization: Building the Moat\u003c\/h3\u003e\n\u003cp\u003eReplicating this isn't like copying a simple device; it’s about replicating the entire workflow and data set. The \u003cstrong\u003eImitability\u003c\/strong\u003e barrier is high because it requires mastering the complex physics of ultrasound ablation within an MRI environment, protected by intellectual property. What this estimate hides is the difficulty in securing the necessary regulatory clearances for such an integrated system.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eOrganization\u003c\/strong\u003e is focused, which turns potential into reality. As of Q3-2025, they had \u003cstrong\u003e70\u003c\/strong\u003e systems installed, and Q3 revenue hit \u003cstrong\u003e$5.3 million\u003c\/strong\u003e, up \u003cstrong\u003e87%\u003c\/strong\u003e year-over-year, with a gross margin of \u003cstrong\u003e74.3%\u003c\/strong\u003e. That growth shows they are effectively selling, installing, and supporting the platform. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e2. Proprietary AI and Closed-Loop Temperature Control\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe TULSA-PRO system combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control. The TULSA Procedure heats prostate tissue to \u003cstrong\u003e55-57°C\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThis software layer ensures precise heating to the target temperature while protecting surrounding tissue, key for patient outcomes. The TULSA-PRO installed base stands at \u003cstrong\u003e70\u003c\/strong\u003e systems as of Q3 2025, with a target of at least \u003cstrong\u003e75\u003c\/strong\u003e by year-end 2025.\u003c\/p\u003e\n\u003cp\u003eThe technology is designed for customizable and predictable radiation-free ablation. Approximately \u003cstrong\u003e60%\u003c\/strong\u003e of commercially treated patients require whole gland ablation, while the remaining \u003cstrong\u003e40%\u003c\/strong\u003e receive partial gland ablation.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eWhile AI is common, the specific, validated, closed-loop control within an MRI suite is specialized. The Thermal Boost module, the first TULSA AI module, is used in up to \u003cstrong\u003e50%\u003c\/strong\u003e of TULSA patients being treated in Europe.\u003c\/p\u003e\n\u003cp\u003eEuropean surgeons indicated Thermal Boost resulted in improved treatment outcomes in \u003cstrong\u003e88%\u003c\/strong\u003e of their prostate cancer cases.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating the validated, real-time feedback loop takes time and clinical data. The company is working on an AI module based on a database of successful physician-created treatment designs.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Component\u003c\/td\u003e\n\u003ctd\u003eStatus\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTULSA-AI Thermal Boost (CE-Marked)\u003c\/td\u003e\n\u003ctd\u003eUsed in up to \u003cstrong\u003e50%\u003c\/strong\u003e of European TULSA patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTULSA-AI Module (FDA Cleared)\u003c\/td\u003e\n\u003ctd\u003eThermal Boost received FDA 510(k) clearance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFuture AI Module\u003c\/td\u003e\n\u003ctd\u003eIn development for automated treatment plan creation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis is central to their value proposition, driving the high gross margin of \u003cstrong\u003e74.3%\u003c\/strong\u003e in Q3-2025.\u003c\/p\u003e\n\u003cp\u003eFinancial Data for Q3 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue: \u003cstrong\u003e$5.3 million\u003c\/strong\u003e, up \u003cstrong\u003e87%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eGross Margin: \u003cstrong\u003e74.3%\u003c\/strong\u003e, up from \u003cstrong\u003e63.1%\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eRecurring Revenue: \u003cstrong\u003e$4.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss: \u003cstrong\u003e$8.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Position (as of Sept 30, 2025): \u003cstrong\u003e$24.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eIt’s a key differentiator now, but the pace of AI development means it needs constant updating. Analysts remain unanimously positive with no 'hold' or 'sell' ratings.\u003c\/p\u003e\n\u003cp\u003eThe TULSA technology has a potential addressable market of up to \u003cstrong\u003e600,000\u003c\/strong\u003e patients per year in the United States.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e3. Regulatory Clearances (FDA 510(k) and CE Mark)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Access to the U.S. and European markets for the TULSA-PRO® system, which generated $4.2 million in revenue in Q4 2024 and contributed to a Full Year 2024 revenue of approximately $10.7 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: The TULSA-PRO® system achieved CE Mark in April 2016 and FDA 510(k) clearance in August 2019. This was supported by the TACT Pivotal Clinical Trial which enrolled 115 patients across 13 research sites.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTACT Pivotal Clinical Trial Enrollment: 115 subjects.\u003c\/li\u003e\n\u003cli\u003eResearch Sites for TACT Trial: 13.\u003c\/li\u003e\n\u003cli\u003eFDA 510(k) Clearance Date (TULSA-PRO®): August 2019.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: The regulatory pathway represents a significant, time-consuming, and expensive barrier to entry, requiring substantial investment in clinical evidence generation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCost Component (General Estimate)\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Total 510(k) Cost Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$30,000\u003c\/strong\u003e to \u003cstrong\u003e$44,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 FDA 510(k) User Fee (Large Business)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$12,845\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Testing Cost (Average for Clients)\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e$100K\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: The company structure is built to support and maintain these critical clearances, evidenced by ongoing clinical trial enrollment and the launch of subsequent AI modules like the Contouring Assistant, which also received 510(k) clearance in May 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. These clearances are necessary prerequisites for market participation rather than a sustainable long-term differentiator in the regulatory landscape.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e4. High Gross Margin on Consumables\/Recurring Revenue\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The 74.3% gross margin in Q3-2025 shows strong unit economics on the disposable components of the procedure. Recurring revenue, which includes TULSA-PRO® consumables, lease of capital equipment, and services, was approximately \\$4.1 million for the quarter ended September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many device companies struggle to achieve this level of margin early in commercialization. The Q3-2025 gross margin of 74.3% represents an increase of 1,119 basis points year-over-year from 63.1% in Q3-2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can copy the device, but achieving this margin requires scale and efficient supply chain management. Gross margin expansion in Q3-2025 was primarily due to manufacturing operating at higher efficiency rates based on improvements that have been implemented.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The shift to a capital sales model is designed to increase the volume feeding this high-margin recurring stream. The TULSA-PRO installed base stood at 70 systems as of Q3-2025, with an expectation to reach at least 75 by the end of the year. The company is pursuing national and regional commercial payer coverage with a projected annual revenue potential of \\$85 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. If they maintain volume, this margin profile fuels R\u0026amp;D and sales expansion.\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics for Q3-2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3-2025 Value (USD)\u003c\/td\u003e\n\u003ctd\u003eQ3-2024 Value (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$2.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring Revenue (Consumables\/Lease\/Service)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital Equipment Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eTULSA-PRO System Utilization and Pipeline:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTULSA-PRO qualified sales pipeline stood at 93 new systems in “Verify, Negotiate and Contracting” stages as of Q3-2025.\u003c\/li\u003e\n\u003cli\u003eThe installed base of TULSA-PRO increased to 67 systems prior to Q3-2025 results, with an expectation to reach at least 75 by the end of the year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRevenue Composition for Q3-2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRecurring – non-capital revenue: \\$4.1 million.\u003c\/li\u003e\n\u003cli\u003eOne-time sale of capital equipment: \\$1.2 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e5. Growing Installed Base and Capital Sales Pipeline\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe installed base and the active capital sales pipeline represent the current commercial traction and near-term revenue visibility for Profound Medical Corp.'s TULSA-PRO platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The current TULSA-PRO installed base stands at \u003cstrong\u003e70\u003c\/strong\u003e systems as of the third quarter ended September 30, 2025. This installed base is the direct driver for recurring, non-capital revenue streams, which totaled approximately \u003cstrong\u003e$4.1 million\u003c\/strong\u003e in Q3 2025. The total revenue for Q3 2025 reached a record \u003cstrong\u003e$5.3 million\u003c\/strong\u003e, with capital equipment sales contributing \u003cstrong\u003e$1.2 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The near-term sales momentum is evidenced by the TULSA-PRO qualified sales pipeline, which currently includes \u003cstrong\u003e93\u003c\/strong\u003e new systems classified within the “Verify, Negotiate and Contracting” stages. This pipeline suggests a significant near-term conversion opportunity beyond the existing base.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors face the challenge of replicating the established installed base and the associated clinical experience and utilization patterns that generate recurring revenue. The time and sales effort required to reach \u003cstrong\u003e70\u003c\/strong\u003e installed systems is a barrier to rapid imitation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is focused on converting the existing pipeline, with an expectation to reach at least \u003cstrong\u003e75\u003c\/strong\u003e installs by the end of the year. The organization is actively managing the transition to a model that balances capital sales with recurring revenue generation, as demonstrated by the Q3 2025 revenue mix.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e The current advantage is temporary, contingent upon the successful and timely conversion of the \u003cstrong\u003e93\u003c\/strong\u003e-system pipeline and continued growth in utilization, which drove the Q3 2025 gross margin to \u003cstrong\u003e74.3%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe utilization of the installed base in Q3 2025 reflects the diversity of conditions being treated:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e79%\u003c\/strong\u003e of patients were treated for prostate cancer only.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e14%\u003c\/strong\u003e were hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4.5%\u003c\/strong\u003e were salvage cases.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2.5%\u003c\/strong\u003e were men with BPH only.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe following table summarizes key financial and operational metrics related to the installed base performance for the third quarter ended September 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount \/ Value\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTULSA-PRO Installed Base (End of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003eFoundation for recurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified Sales Pipeline\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e93\u003c\/strong\u003e new systems\u003c\/td\u003e\n\u003ctd\u003eSystems in 'Verify, Negotiate and Contracting' stages\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-End Install Target\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e75\u003c\/strong\u003e installs\u003c\/td\u003e\n\u003ctd\u003eCompany expectation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecord revenue, up \u003cstrong\u003e87%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Recurring Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom consumables, lease, and warranties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Capital Equipment Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOne-time sale of capital equipment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e1,119\u003c\/strong\u003e basis points year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand (As of Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$24.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLiquidity position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e6. Favorable CMS Reimbursement Status\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe establishment of Category 1 CPT codes for the TULSA procedure, effective January 1, 2025, by the U.S. Centers for Medicare \u0026amp; Medicaid Services (CMS), provides a significant economic foundation for adoption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe TULSA procedure's assignment to Urology Ambulatory Payment Classification (APC) \u003cstrong\u003eLevel 7\u003c\/strong\u003e, the highest in its category for prostate treatments, directly translates to superior financial attractiveness for providers compared to incumbent procedures. The Medicare national average facility reimbursement for the TULSA Complete Procedure (CPT 55882) is positioned to be \u003cstrong\u003e25% higher\u003c\/strong\u003e than that for robotic radical prostatectomy under the 2025 final rule.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAchieving Urology APC \u003cstrong\u003eLevel 7\u003c\/strong\u003e status is rare, as TULSA-PRO is cited as the first and only prostate treatment to attain this classification as of the 2025 OPPS update. This favorable, superior reimbursement against a major incumbent procedure is inherently rare and powerful in influencing capital expenditure decisions by healthcare facilities.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReplicating this specific economic advantage requires successfully navigating the multi-year regulatory and clinical evidence pathway necessary to secure Category 1 CPT codes and a high APC assignment from CMS. The TULSA-PRO system received its initial FDA 510(k) clearance in \u003cstrong\u003eAugust 2019\u003c\/strong\u003e, indicating the multi-year timeline required to reach this reimbursement milestone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization must actively manage payer relations and continuously provide clinical data to defend and maintain this favorable status against evolving payment schedules and competitive procedural advancements. The company must also ensure proper utilization of the three new CPT codes based on physician involvement and site of service to realize the full economic benefit.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe economic advantage is positioned as \u003cstrong\u003eSustained\u003c\/strong\u003e due to the high barrier to imitation and the direct impact of reimbursement levels on physician adoption decisions for new capital equipment.\u003c\/p\u003e\n\n\u003cp\u003eThe specific 2025 Medicare National Average facility reimbursement figures for the TULSA Complete Procedure (CPT 55882) are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSite of Service\u003c\/th\u003e\n\u003cth\u003eAPC Level\u003c\/th\u003e\n\u003cth\u003eMedicare National Average Payment\u003c\/th\u003e\n\u003cth\u003eRelative Value Units (RVU)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital Outpatient (HOPD)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLevel 7\u003c\/strong\u003e (APC 5377)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,992\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18.01\u003c\/strong\u003e (Facility)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmbulatory Surgical Center (ASC)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eLevel 7\u003c\/strong\u003e (APC 5377)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,728\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18.01\u003c\/strong\u003e (Facility)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Office\/Non-Facility (OBL)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e276.65\u003c\/strong\u003e (Non-Facility)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe new payment structure represents significant increases over prior proposed rules:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHospital payment increased approximately \u003cstrong\u003e41%\u003c\/strong\u003e over the Proposed Rule amounts.\u003c\/li\u003e\n\u003cli\u003eASC payment increased approximately \u003cstrong\u003e49%\u003c\/strong\u003e over the Proposed Rule amounts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe TULSA procedure codes carry a \u003cstrong\u003e0-day global period\u003c\/strong\u003e, meaning payment covers only the work performed on the day of the procedure, allowing for separate billing of pre- or post-procedure Evaluation and Management (E\/M) services.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e7. Clinical Validation from CAPTAIN Trial Progress\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue: Positive data from this trial, comparing TULSA to radical prostatectomy, is expected to drive new society guidelines, effectively requiring awareness of TULSA.\u003c\/h\u003e\n\u003cp\u003eThe CAPTAIN trial, a Level 1 randomized controlled trial (RCT), demonstrated statistically significant improvement in post-operative experience for the TULSA procedure versus Robotic Prostatectomy (RP) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer.\u003c\/p\u003e\n\u003cp\u003eKey perioperative comparison data presented at the American Urological Association (AUA) Annual Meeting on April 28, 2025, includes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eTULSA Median (IQR)\u003c\/th\u003e\n\u003cth\u003eRP Median (IQR)\u003c\/th\u003e\n\u003cth\u003eP-value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood Loss (mL)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e (0-0)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100\u003c\/strong\u003e (100-200)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;\u003cstrong\u003e0.001\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLength of Stay (Days)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0.29\u003c\/strong\u003e (0.27-0.32)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.24\u003c\/strong\u003e (1.12-1.36)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;\u003cstrong\u003e0.001\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePatient-reported outcomes showed significant advantages for TULSA:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNRS (Numeric Rating Scale) pain: Significantly lower post-operative pain through post-treatment day \u003cstrong\u003e6\u003c\/strong\u003e, p\u0026lt;\u003cstrong\u003e0.05\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHealth-related QOL (EQ-5D-5L VAS): Significantly higher overall health for all \u003cstrong\u003e30\u003c\/strong\u003e days measured after treatment, p\u0026lt;\u003cstrong\u003e0.05\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMobility Issues (First Month): \u003cstrong\u003e0%\u003c\/strong\u003e for TULSA vs. \u003cstrong\u003e12%\u003c\/strong\u003e for RP, p=\u003cstrong\u003e0.001\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSelf-Care Issues (First Month): \u003cstrong\u003e3%\u003c\/strong\u003e for TULSA vs. \u003cstrong\u003e17%\u003c\/strong\u003e for RP, p=\u003cstrong\u003e0.005\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUsual Activities Issues (First Month): \u003cstrong\u003e17%\u003c\/strong\u003e for TULSA vs. \u003cstrong\u003e40%\u003c\/strong\u003e for RP, p=\u003cstrong\u003e0.008\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eRarity: High. A head-to-head pivotal trial showing superiority in side-effect profiles is a massive market mover.\u003c\/h\u003e\n\u003cp\u003eThe CAPTAIN trial is noted as the first randomized controlled trial comparing an emerging technology (TULSA) head-to-head with the standard of care (Robotic Radical Prostatectomy) to successfully recruit to target enrollment.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability: High. Running a large, successful, multi-center trial is a huge resource commitment few can match quickly.\u003c\/h\u003e\n\u003cp\u003eThe trial recruited patients starting in 2022 across 20 sites in the United States, two in Canada, and one in Europe, totaling 23 international sites. As of January 2025, \u003cstrong\u003e201\u003c\/strong\u003e patients were randomized.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization: High. Management is clearly banking on this data to unlock significant future growth.\u003c\/h\u003e\n\u003cp\u003eManagement has reiterated confidence in full-year revenue growth of \u003cstrong\u003e70%\u003c\/strong\u003e to \u003cstrong\u003e75%\u003c\/strong\u003e for 2025 over 2024 revenue of approximately $\u003cstrong\u003e10.7\u003c\/strong\u003e million. The company reported Q2 2025 revenue of $\u003cstrong\u003e2.2\u003c\/strong\u003e million, with a net loss of $\u003cstrong\u003e15.7\u003c\/strong\u003e million, or $\u003cstrong\u003e0.52\u003c\/strong\u003e per share, and held cash of $\u003cstrong\u003e35.2\u003c\/strong\u003e million as of June 30, 2025. The stock closed at $\u003cstrong\u003e4.77\u003c\/strong\u003e on Nasdaq on April 29, 2025, with a reported Market Cap of C$\u003cstrong\u003e197.1\u003c\/strong\u003eM.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained. Guideline changes create a long-lasting, structural tailwind for adoption.\u003c\/h\u003e\n\u003cp\u003eThe positive data is expected to impact insurance coverage policies and patient demand, positioning TULSA as a mainstream treatment option.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e8. TULSA-AI Volume Reduction Software for BPH\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe TULSA-AI Volume Reduction Module extends the Total Addressable Market (TAM) for prostate disease from an estimated 200,000 patients annually to approximately 600,000 patients annually by specifically targeting Benign Prostatic Hyperplasia (BPH) patients. This expansion creates a potential revenue opportunity of \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e annually, based on an average procedure cost of \u003cstrong\u003e$4,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eClinical data from a Phase II study at the University of Turku supports this value proposition:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInternational Prostate Symptom Scores (IPSS) decreased from 17 to 4.\u003c\/li\u003e\n\u003cli\u003ePeak urine flow rates increased from 11.1 mL\/s to 18.3 mL\/s.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e96%\u003c\/strong\u003e of patients discontinued BPH medications post-procedure.\u003c\/li\u003e\n\u003cli\u003eTreatment time is reduced to an expected 60–90 minutes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePre-TULSA-AI (BPH)\u003c\/th\u003e\n\u003cth\u003ePost-TULSA-AI (BPH)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Addressable Market (Patients)\u003c\/td\u003e\n\u003ctd\u003eEstimated 200,000 (Prostate Disease Total Estimate)\u003c\/td\u003e\n\u003ctd\u003eEstimated 600,000 (Prostate Disease Total Estimate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Annual Revenue Opportunity\u003c\/td\u003e\n\u003ctd\u003eImplied lower base\u003c\/td\u003e\n\u003ctd\u003ePotential \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Procedure Cost\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPSS Score\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak Urine Flow Rate\u003c\/td\u003e\n\u003ctd\u003e11.1 mL\/s\u003c\/td\u003e\n\u003ctd\u003e18.3 mL\/s\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe TULSA-AI module demonstrates product line extension capability beyond the initial prostate cancer indication, which is a moderate indicator of rarity in the context of platform utilization.\u003c\/p\u003e\n\u003cp\u003eIn Q3 2024, 2% of patients treated with TULSA-PRO were for BPH only, indicating a pre-existing, albeit small, presence in this segment prior to the dedicated module launch.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe solution leverages the existing TULSA-PRO platform, which has 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is CE marked. The TULSA-PRO installed base reached 67 units as of Q3 2025, with an expectation to reach at least 75 by year-end 2025.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe launch of the TULSA-AI Volume Reduction module for BPH was announced in late November 2025, with presentations at RSNA starting December 1, 2025. The first commercial BPH treatment utilizing the module occurred in June 2025.\u003c\/p\u003e\n\u003cp\u003eFinancial context from Q3 2025 preliminary results shows record total revenues in the range of \u003cstrong\u003e$5.2 million\u003c\/strong\u003e to \u003cstrong\u003e$5.3 million\u003c\/strong\u003e, representing YoY growth of 84% to 87%. Gross margin for Q3 2025 was expected at approximately 72%, compared to 64% in Q3 2024.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe advantage is temporary as it opens a new market segment, but competitors in the BPH space, such as Medtronic (MDT) and Johnson \u0026amp; Johnson (JNJ), dominate with legacy devices.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eProfound Medical Corp. (PROF) - VRIO Analysis: \u003cstrong\u003e9. Strategic Partnership with Siemens for TULSA+\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eThe collaboration with Siemens Healthineers, announced on February 27, 2024, aims to market a complete therapeutics solution combining TULSA-PRO® with the MAGNETOM Free.Max MRI scanner, termed TULSA+.\u003c\/p\u003e\n\n\u003ch3 style=\"margin-top: 1em; margin-bottom: 0.5em;\"\u003eValue\u003c\/h3\u003e\n\u003cp\u003eCombining TULSA technology with the MAGNETOM Free.Max MRI creates an attractive, potentially lower-cost, form-factor solution for urology practices.\u003c\/p\u003e\n\n\u003ch3 style=\"margin-top: 1em; margin-bottom: 0.5em;\"\u003eRarity\u003c\/h3\u003e\n\u003cp\u003ePartnering with a major OEM like Siemens for co-marketing is a significant strategic move.\u003c\/p\u003e\n\n\u003ch3 style=\"margin-top: 1em; margin-bottom: 0.5em;\"\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe collaboration is officially described as non-exclusive.\u003c\/p\u003e\n\n\u003ch3 style=\"margin-top: 1em; margin-bottom: 0.5em;\"\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe planned initiation of sales for the combined solution is expected in 2025. The new sales and marketing partnership was announced in December.\u003c\/p\u003e\n\n\u003ch3 style=\"margin-top: 1em; margin-bottom: 0.5em;\"\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eSpecification\/Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Announcement Date\u003c\/td\u003e\n\u003ctd\u003eInitial Announcement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 27, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined Solution Name\u003c\/td\u003e\n\u003ctd\u003eTULSA+\u003c\/td\u003e\n\u003ctd\u003eTULSA-PRO® + MAGNETOM Free.Max\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAGNETOM Free.Max Field Strength\u003c\/td\u003e\n\u003ctd\u003eMRI Scanner Specification\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.55 Tesla\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAGNETOM Free.Max Bore Size\u003c\/td\u003e\n\u003ctd\u003eMRI Scanner Specification\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e80 cm\u003c\/strong\u003e wide-bore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales Initiation Expectation\u003c\/td\u003e\n\u003ctd\u003eCombined Solution Launch Timeline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS Reimbursement Level (Effective Jan 1)\u003c\/td\u003e\n\u003ctd\u003eAmbulatory Payment Classification (APC)\u003c\/td\u003e\n\u003ctd\u003eUrology Level \u003cstrong\u003e7\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRelevant Financial and Procedural Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2024 Revenue (ended September 30, 2024): \u003cstrong\u003e$2.83 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2024 Recurring Revenue: \u003cstrong\u003e$2.65 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Revenue Guidance Range: \u003cstrong\u003e$11.0 million\u003c\/strong\u003e to \u003cstrong\u003e$12.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Position as of September 30, 2024: \u003cstrong\u003e$27.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Revenue: Approximately \u003cstrong\u003e$2.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$5.29 million\u003c\/strong\u003e (exceeded consensus of \u003cstrong\u003e$4.98 million\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eGross Margin (Q2 2025): \u003cstrong\u003e73%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTULSA Procedure CPT Codes: \u003cstrong\u003eThree new CPT® Category 1 codes\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 style=\"margin-top: 1em; margin-bottom: 0.5em;\"\u003eFinance\u003c\/h3\u003e\n\u003cp\u003eDraft 13-week cash view by Friday.\u003c\/p\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516234915989,"sku":"prof-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/prof-vrio-analysis.png?v=1740207813","url":"https:\/\/dcf-model.com\/fr\/products\/prof-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}